Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 46,471

Document Document Title
WO/2019/009354A1
The purpose of the present invention is to provide a composition for amelioration of dysuria, containing, in addition to a natural substance such as nobiletin which is a prior art, a component derived from a natural substance that is sim...  
WO/2019/009355A1
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that u...  
WO/2019/009436A1
The present invention relates to: a compound in which a carbonyl group in serine is linked by peptide bonding or ester bonding to a terminal group in a polymeric carrier having multiple terminal groups directly or through a linker; a dru...  
WO/2019/010201A1
In one embodiment, the invention' provides a chimeric antigen receptor (CAR) T cell which is conjugated to a bi-functional molecule which is specific for both an extracellular binding domain of the chimeric antigen receptor (CAR) T cell ...  
WO/2019/010316A1
Disclosed herein are methods for treating hyperplastic tissue growths, including benign prostatic hyperplasia, in a subject by injection of compositions comprising antineoplastic agents, including taxanes such as paclitaxel and docetaxel...  
WO/2019/010092A1
Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fi...  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2019/006113A1
The present invention relates to organoids derived from a single brain cell, such as, for example, a Glioblastoma (GBM) cell, and methods and compositions relating to the production and use thereof, including cell culture medium for prod...  
WO/2019/004421A1
The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof. In the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is -C(=O)-...  
WO/2019/002473A1
The present invention provides a composition for treating acute urinary retention and reducing the recurrences rates in a male patient by administering a composition for treating acute urinary retention, said composition comprises at lea...  
WO/2019/002571A1
This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prev...  
WO/2019/003433A1
The present invention provides: a novel benzazepine compound which is represented by formula (1) and has vasopressin V1a and V2 antagonism, or a salt thereof; and a pharmaceutical use thereof. [In formula, R1 represents optionally substi...  
WO/2019/003104A1
The disclosure relates to novel uses and methods for preventing and/or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an A...  
WO/2019/006127A1
The present invention relates to organoids derived from a single cell, such as a kidney cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and metho...  
WO/2018/234372A1
Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury.  
WO/2018/233604A1
Provided are an application of a plasminogen to regulate and control the GLP-1/GLP-1R and the treatment of GLP-1/GLP-1R related diseases.  
WO/2018/229739A1
This dose determination program is a computer-executed program that determines the dose of an erythropoiesis-stimulating agent, and that executes, in a computer, a step (S1) for acquiring a predetermined target hemoglobin concentration t...  
WO/2018/230504A1
A method for producing tablets, said method comprising: a step for dissolving dutasteride in a solubilizing agent to give a solution; a step for adding to the solution an adsorbent and powdering the resultant mixture to give a powder; a ...  
WO/2018/229284A1
R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linki...  
WO/2018/225673A1
Disclosed are: a method for manufacturing a therapeutic composition containing mammalian cells, said method comprising dispersing the mammalian cells in an aqueous glucose solution having a concentration of about 3-10% or Ringer's acetat...  
WO/2018/226732A1
Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers...  
WO/2018/226507A1
Methods for detecting a glycine amidinotransferase (GATM) mutation in a biological sample from a patient are disclosed. Also disclosed are related methods for diagnosing a renal disorder in a patient, treating a patient suffering from a ...  
WO/2018/226771A1
The present invention is directed to pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such ...  
WO/2018/224063A3
The invention provides novel solid forms of elagolix and its esters of formula (I), optionally with acids or with polymers, methods of preparation and uses thereof. These solid forms are particularly suitable as intermediates of synthesi...  
WO/2018/224990A1
The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 50 mg to about 100 mg (e.g., about 75 mg) of vibegron per day. The present...  
WO/2018/224989A1
The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day. The present ...  
WO/2018/227063A1
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.  
WO/2018/218961A1
A use of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into vario...  
WO/2018/221521A1
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...  
WO/2018/221543A1
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...  
WO/2018/222655A1
Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or s...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/222472A1
The present invention relates to methods of using dulaglutide for the treatment of chronic kidney disease in patients having moderate to late stage chronic kidney disease.  
WO/2018/221433A1
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...  
WO/2018/221291A1
[Problem] Various side effects have been reported for conventional therapeutic drugs for hyperactive bladder, and a prophylactic or therapeutic agent for hyperactive bladder without causing side effects is desired. [Solution] Provided is...  
WO/2018/216228A1
The purpose of the present invention is to establish, as one of bladder regenerative medical techniques, novel treatment which transplants a bone marrow-derived cell structure into a bladder and attempts to regenerate a functional bladde...  
WO/2018/214961A1
The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceuti...  
WO/2018/217803A3
Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods o...  
WO/2018/214222A1
Provided are a particular compound of 1-pyridine-6-methoxy-9-(3-methylbenzyl)β-carboline and a synthetic method and application thereof. The compound has significant anti-renal fibrosis activity in vitro and can be used in preparing a d...  
WO/2018/216743A1
A method for producing renal progenitor cells from pluripotent stem cells, comprising steps (i) to (vi): (i) culturing the pluripotent stem cells in a culture medium containing FGF2, BMP4, a GSK-3β inhibitor and retinoic acid or a deriv...  
WO/2018/214736A1
Provided are a polyhydroxyphthalazinone compound, a preparation method therefor and the use thereof, wherein the general formula of the chemical structure of the polyhydroxyphthalazinone compound is as shown by formula (I). The polyhydro...  
WO/2018/210449A1
The invention discloses WNK signalling inhibitors, in particular closantel, for use in the prevention and treatment of disorders caused and/or characterized by elevated levels of serum fibroblast growth factor (FGF23), especially chronic...  
WO/2018/213715A1
Provided herein are methods and compositions related to treating and/or preventing sleep disorders and for improving sleep health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comp...  
WO/2018/209679A1
An aloe-pig kidney compound composition, comprising aloe extract dried powder and pig kidney powder. The aloe extract dried powder is obtained by concentrating decolorized aloe gel by 200:1, drying and grinding same into powder; and the ...  
WO/2018/210066A1
A combined externally-applied drug for treating prostatic diseases, characterized by comprising three components, which are a pre-immunization component, a focus active component, and a double-rib active component. The pre-immunization c...  
WO/2018/210207A1
A compound as represented by formula (I), and optical isomers, solvates, pharmaceutically-acceptable salts, or prodrugs thereof. The present invention has urate transporter 1 (URAT1) inhibitory activity, can be used for treatment of gout...  
WO/2018/212136A1
The present invention addresses the problem of providing: an antibody having an internalization activity of binding to CDH6; an antibody-drug conjugate consisting of the aforesaid antibody and a drug having an antitumor activity; a medic...  
WO/2018/206358A1
The invention relates to a combination drug with increased storage stability containing chondoitin sulfate (4.5 mg/ml), hyaluronic acid (16 mg/ml), a phosphate buffer (pH 6.1 to 7.9) and optionally an electrolyte (e.g., an alkali salt, e...  
WO/2018/206357A1
The invention relates to a composition, in particular a pharmaceutical composition, which is suitable in particular for the prophylactic and/or therapeutic treatment preferably of inflammatory diseases of the urogenital tract, in particu...  
WO/2018/206078A1
The present invention concerns cocrystals of finasteride and a carboxylic acid, a method of their preparation and a pharmaceutical formulation comprising said cocrystals. In addition the invention relates to said cocrystals for use in th...  

Matches 1 - 50 out of 46,471